The SHIGETECVAX consortium and Eveliqure included in the “Success Story” series of the Austrian Research Promotion Agency (FFG)
To read the article (only available in German), please click this link. (https://www.ffg.at/news/success-story-shigetecvax-leistbarer-impfstoff-gegen-durchfallerkrankungen)
Further information:https://www.linkedin.com/posts/eveliqure-biotechnologies_success-story-shigetecvax-leistbarer-activity-6593423042813153280-w2cp
Comments